ADHF

AcronymDefinition
ADHFAcute Decompensated Heart Failure
ADHFAmerican Digestive Health Foundation
ADHFAgility Dog Hall of Fame (golden retrievers)
References in periodicals archive ?
The aim of this study is to determine the early evolution, associations, and correlations of high-sensitivity troponin T (hsTnT) in ADHF.
High-sensitivity troponin T: a biomarker for diuretic response in decompensated heart failure patients
Briefly, 599 dyspneic patients treated in an urban ED were enrolled in a study for the purpose of validating the value of amino-terminal pro-B-type natriuretic peptide (NT-proBNP) for diagnosis of ADHF in this setting.
Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients
Cardioxyl's lead program is focused on the development of proprietary nitroxyl donors for the treatment of acute decompensated heart failure (ADHF).
CARDIOXYL INITIATES PHASE I/IIA STUDY IN HEART FAILURE
The ADHF's Digestive Health Initiative (DHI) currently is involved in a number of educational efforts, including the Ulcer, Colorectal Cancer and Viral Hepatitis Education Campaigns.
Dr. Dan Talks To You About The ABC's of Viral Hepatitis A, B & C
Additionally, the company expects to launch a 500-patient multi-centre Phase 2b clinical trial for TRV027 in ADHF patients by year end.
Trevena Inc awarded the US patent for lead Phase 2 compound TRV027 in treating acute decompensated heart failure patients
2 August 2010 - US pharmaceutical company Cardioxyl Pharmaceuticals Inc said today it has achieved positive safety and tolerability results in the first clinical study of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure (ADHF).
Cardioxyl reports ADHF study data, raises USD15m in funding
The study, NIL-CDNP-CT005, was designed to provide additional information on the safety and tolerability of CD-NP when infused for up to 72 hours in patients with ADHF and mild to moderate renal insufficiency.
Nile Therapeutics Inc completes last dosing in Phase II study of CD-NP for ADHF
Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) with worsening renal function.
Procyrion Receives FDA Breakthrough Device Designation for Aortix System
Acute decompensated heart failure (ADHF) is associated with abnormal hemodynamics especially left ventricular filling pressure and cardiac output.
Validating Left Ventricular Filling Pressure Measurements in Patients with Congestive Heart Failure: CardioMEMS[TM] Pulmonary Arterial Diastolic Pressure versus Left Atrial Pressure Measurement by Transthoracic Echocardiography
In the United States, ADHF accounts for approximately half of all heart failure-related causes of hospitalisation.
Renova Therapeutics to Receive Stresscopin Investigational New Drug File from Janssen
In the BACH Study, amongst 1641 patients presenting to the emergency department with dyspnea, MR-proANP >120 pmol/L proved noninferior to BNP >100 pg/mL for the diagnosis of acute decompensated HF (ADHF); MR-proANP added to the utility of BNP in patients with intermediate BNP values and with obesity but not in renal insufficiency, the elderly, or patients with edema (7).
Beyond Natriuretic Peptides for Diagnosis and Management of Heart Failure
Nevertheless, a significant proportion of the patients admitted to the hospital for acute decompensated heart failure (ADHF) is discharged with unresolved congestion.
Natriuretic Peptides as Biomarkers for Congestive States: The Cardiorenal Divergence
Acronyms browser ?
Full browser ?